Paper81964
Tamoxifen and thrombosis.
Nevasaari K and 2 others. Lancet, 1978. Cited by 73 papers, by iCite.
Cite this record
ConductScience Library. Tamoxifen and thrombosis. Papers, record 81964. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/81964
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Tamoxifen | Major topic |
| Thrombophlebitis | Major topic |
| Adult | |
| Aged | |
| Female | |
| Humans | |
| Leg | |
| Middle Aged |
Source PubMed
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 73 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 33567864 | Cancer Therapy-Associated Thrombosis. | Arterioscler Thromb Vasc Biol | 2021 | https://conductscience.org/library/papers/33567864 | PubMed |
| 26648754 | Optimal delivery of male breast cancer follow-up care: improving outcomes. | Breast Cancer (Dove Med Press) | 2015 | https://conductscience.org/library/papers/26648754 | PubMed |
| 25832603 | Approach to chemotherapy-associated thrombosis. | Vasc Med | 2015 | https://conductscience.org/library/papers/25832603 | PubMed |
| 10665480 | Antiestrogens--tamoxifen, SERMs and beyond. | Invest New Drugs | 1999 | https://conductscience.org/library/papers/10665480 | PubMed |
| 10408733 | Clinical pharmacology of selective estrogen receptor modulators. | Drugs Aging | 1999 | https://conductscience.org/library/papers/10408733 | PubMed |
| 9663819 | Tamoxifen and risk of idiopathic venous thromboembolism. | Br J Clin Pharmacol | 1998 | https://conductscience.org/library/papers/9663819 | PubMed |
| 8504018 | A risk-benefit assessment of tamoxifen therapy. | Drug Saf | 1993 | https://conductscience.org/library/papers/8504018 | PubMed |
| 8435478 | Hormone resistance, invasiveness, and metastatic potential in breast cancer. | Breast Cancer Res Treat | 1993 | https://conductscience.org/library/papers/8435478 | PubMed |
| 8242225 | Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. | Br J Pharmacol | 1993 | https://conductscience.org/library/papers/8242225 | PubMed |
| 7507033 | Tamoxifen as adjuvant therapy in breast cancer. Current status. | Drugs | 1993 | https://conductscience.org/library/papers/7507033 | PubMed |
| 6423014 | Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications. | Breast Cancer Res Treat | 1983 | https://conductscience.org/library/papers/6423014 | PubMed |
| 3228593 | Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. | Breast Cancer Res Treat | 1988 | https://conductscience.org/library/papers/3228593 | PubMed |
| 2146053 | Chemotherapy enhances endothelial cell reactivity to platelets. | Clin Exp Metastasis | 1990 | https://conductscience.org/library/papers/2146053 | PubMed |
| 1419616 | Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women. | Br J Cancer | 1992 | https://conductscience.org/library/papers/1419616 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/81964
GET https://conductscience.org/api/papers/v1/81964/authors